 Home > Active Ingredient News > Antitumor Therapy > CSCO conference express a multicenter, retrospective study of pyrrotinib combined with vinorelbine in the treatment of HER2-positive MBC

CSCO conference express a multicenter, retrospective study of pyrrotinib combined with vinorelbine in the treatment of HER2-positive MBC

 Last Update: 2021-10-10
 Source: Internet
 Author: User

As we all know, pyrrotinib is our self-developed anti-HER2 drug, which can irreversibly inhibit HER1, HER2 and HER4
.

In the past, it has been used clinically in combination with capecitabine to treat HER2-positive metastatic breast cancer that has failed trastuzumab treatment, and the guidelines also regard it as a first-level recommended treatment plan .

Pirotinib combined with vinorelbine is safe and effective, especially in second-line treatment and patients who have never received lapatinib and brain metastases

In the combination therapy with pyrrotinib, oral vinorelbine and intravenous vinorelbine show similar effects.

This study is the first to systematically explore the efficacy and safety of pyrrotinib combined with vinorelbine in HER2+MBC

Pirotinib combined with vinorelbine is safe and effective, especially in second-line treatment and patients who have never received lapatinib and brain metastases

In the combination therapy with pyrrotinib, oral vinorelbine and intravenous vinorelbine show similar effects.

Note: This article has been compiled by Professor Wang Biyun from the Cancer Hospital of Fudan University in the live broadcast of the CSCO conference and I have to leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dacarbazine CAS 4342-03-4 for Scientific Research Chemical Reagents Use only

CAS No.: 4342-03-4

Pharmacy Grade

$4-5/G FOB

Lapatinib 99% white powder CAS231277-92-2 bulk Lapatinib

CAS No.: 231277-92-2

Pharmacy Grade

$88-98/KG FOB

Mitomycin C

CAS No.: 50-07-7

Industrial Grade

$0.1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

CSCO conference express a multicenter, retrospective study of pyrrotinib combined with vinorelbine in the treatment of HER2-positive MBC

As we all know, pyrrotinib is our self-developed anti-HER2 drug, which can irreversibly inhibit HER1, HER2 and HER4 .

As we all know, pyrrotinib is our self-developed anti-HER2 drug, which can irreversibly inhibit HER1, HER2 and HER4
.